KRAS G12D Protein, Human, Recombinant, Biotinylated, GDP-Loaded
N-terminal AviTag™, N-terminal 8XHis
High-purity KRAS G12D protein supplied in a defined GDP-loaded conformation for controlled biochemical workflows, including SPR, BLI, ELISA, pull-down, AlphaScreen, MST, nucleotide exchange assays, SOS1-mediated exchange assays, and oncology drug discovery applications.
Available Sizes
Product Overview
Key Features
- KRAS G12D clinically relevant mutation
- Supplied pre-loaded with GDP
- N-terminal AviTag™, N-terminal 8XHis tagged construct
- Site-specifically biotinylated at the N-terminus
- High purity recombinant protein
- Optimized for binding assays
- Research Use Only (RUO)
Applications
- SPR
- BLI
- ELISA
- Pull-down
- AlphaScreen
- MST
- Nucleotide exchange assays
- SOS1-mediated exchange assays
- Protein–protein interaction studies
- Drug discovery workflows
Technical Notes
On nucleotide loading and the GDP conformation
GDP-loaded KRAS G12D represents the biologically inactive state. While the G12D mutation impairs GTP hydrolysis and favors GTP-bound (active) KRAS in cells, the recombinant protein is supplied GDP-loaded for stability and experimental flexibility. Researchers can initiate exchange to GTP (or non-hydrolyzable analogues such as GppNHp, GMPPNP, or GTPγS) using SOS1 as a guanine nucleotide exchange factor. For assays requiring constitutively active KRAS G12D, please see our GppNHp-loaded version.
On N-terminal biotinylation and effector binding
AviTag biotinylation is at the N-terminus, upstream of the KRAS catalytic domain (aa 10–164). The switch I (aa 30–38) and switch II (aa 60–76) regions that mediate effector binding are in the core domain and are not directly affected by N-terminal tag placement. However, users performing steric-sensitive assays (e.g., antibody epitope mapping near the N-terminus) may prefer C-terminally biotinylated constructs — see KRAS G12V (1–166), Biotinylated at C-terminus (Cat #KRAS12V-B-C-301) for a reference format; C-terminal G12D is available on request.
MgCl₂ is required for nucleotide retention
The storage buffer contains 1 mM MgCl₂, which is essential for Mg²⁺-GDP coordination at the nucleotide binding site. Assay buffers should maintain 1–5 mM MgCl₂. Removal of Mg²⁺ leads to rapid nucleotide dissociation. EDTA should not be used in working buffers.
Biological Context & Applications
Cancer Indications
Pancreatic ductal adenocarcinoma (PDAC), colorectal cancer, non-small cell lung cancer, appendiceal cancer, cholangiocarcinoma, endometrial cancer
Binding Partners
RAF1, PI3K, SOS1, RalGDS
Application Notes
Core mutation for oncology drug discovery workflows
Protein Specifications
| Gene | KRAS |
|---|---|
| Mutation | G12D |
| Nucleotide State | GDP-Loaded |
| Organism | Human |
| Tag | N-terminal AviTag™, N-terminal 8XHis |
| Expression System | E. coli |
| Purity | >90% by Coomassie staining |
| Endotoxin | <1 EU/mg |
| Biotinylated | Yes |
| Oncogenic Status | Oncogenic |
| Assay Compatibility | SPR, BLI, ELISA, Pull-down, AlphaScreen, MST, Nucleotide exchange assays, SOS1-mediated exchange assays |
| UniProt ID | P01116-2 |
| Amino Acid Range | 1-185 |
| Buffer | 20 mM HEPES, pH 7.5, 100 mM NaCl, 1 mM MgCl2, 1 mM 2-mercapthoethanol, 10% glycerol |
| Storage | -80 °C |
Quality Control
- Purity validated by SDS-PAGE
- Identity confirmed by mass spectrometry
- Assay compatibility verified
- A Certificate of Analysis (CoA) is provided with every shipment
Ordering Information
| Size | Catalog No. | Price | Quote |
|---|---|---|---|
| 0.05 mg | KRAS12D-GDP-301-005 | $ 500.00 | Request Quote |
| 0.1 mg | KRAS12D-GDP-301-01 | $ 750.00 | Request Quote |
| 1.0 mg | KRAS12D-GDP-301-1 | $ 5,500.00 | Request Quote |
Typical response time: 1 business day
Custom Services
Need a different format, mutation, or production scale? We offer custom RAS protein engineering tailored to your research.
Alternative KRAS variants, including rare and novel mutations.
His-tag, AviTag™, biotinylation, fluorescent labeling, or tag-free formats.
From research-scale to bulk manufacturing for screening and preclinical work.
Complex formation such as KRAS–RAF-RBD and other binding partners.
Pre-load KRAS proteins with defined nucleotides, including GppNHp (non-hydrolyzable GTP analog) or GDP, for consistent assay-ready performance.
Tell us your mutation, format, or assay requirements and we’ll provide a tailored quote.
Fast turnaround • Dedicated scientific support • Confidential projects
Related Products
Other KRAS mutants and formats available.
Research Use Only. Not for diagnostic or therapeutic use.